OBJECTIVE -Lipocalin-2, a novel adipokine, has been shown to be elevated in obese, insulin-resistant, and diabetic subjects. We therefore sought to study the ex vivo and in vivo effects of insulin on lipocalin-2 levels in humans.
O
besity and the metabolic syndrome are associated with serious cardiometabolic sequelae including insulin resistance, hyperinsulinemia, diabetes, dyslipidemia, and cardiovascular disease (1) . The metabolic syndrome is associated with visceral obesity. Adipose tissue produces cytokines termed "adipokines" that are implicated in the pathogenesis of the metabolic syndrome (2) .
Recently, Yan et al. (3) established lipocalin-2 as a novel adipokine, highly expressed by adipose tissue in murine models of obesity. Also, they demonstrated that lipocalin-2 levels are increased by dexamethasone and tumor necrosis factor-␣ and are reduced by rosiglitazone in murine adipocytes (3) . More recently, Wang et al. (4) reported elevated levels of lipocalin-2 in obesity and diabetes.
We therefore studied the effects of acute and chronic hyperinsulinemia on circulating lipocalin-2 levels via a prolonged insulin-glucose infusion in humans. We also assessed the effects of insulin on lipocalin-2 protein production and secretion into conditioned media from human visceral adipose tissue explants.
RESEARCH DESIGN AND METHODS -We measured circulating lipocalin-2 in six healthy subjects (mean Ϯ SD age 26.5 Ϯ 8 years and BMI 23.2 Ϯ 2.5 kg/m 2 ). To account for the possible diurnal variation in lipocalin-2 levels, we obtained a daily control curve by measuring fasting lipocalin-2 levels at 30-min intervals from 0800 to 1000 h. Subsequently, lipocalin-2 levels were measured at 2-h intervals until 2400 h and then at 0400 h as well as at 30-min intervals from 0800 to 1000 h on day 2. On the following day, the same subjects were subjected to a prolonged insulinglucose infusion for 26 h beginning at 0800 h. Insulin (human Actrapid) was administered intravenously as a priming dose of 0.04 units/kg followed by continuous infusion of 0.5 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 . By choosing this rate of insulin infusion, we expected to achieve hyperinsulinemia with an approximate four-to sixfold elevation of basal insulinemia (5) . Fasting blood samples were drawn at 30-min intervals between 0800 and 1000 h on day 1 and day 2 of the prolonged insulinglucose infusion (the first and the last 2 h of the infusion). Intermediate blood samples were taken at 2-h intervals until 2400 h and then at 0400 h on day 2. Glucose levels were maintained between 4.0 and 6.0 mmol/l.
For adipose tissue explant studies, after an overnight fast, adipose tissue was obtained (0800 -1000 h) from six surgical patients (age 27.5 Ϯ 7 years and BMI 23.8 Ϯ 2.8 kg/m 2 ). Samples were placed into sterile containers containing Medium 199 (Sigma-Aldrich, Gillingham, U.K.) for primary adipose tissue culture.
Exclusion criteria for all subjects included known cardiovascular disease, thyroid disease, neoplasms, current smoking, diabetes, hypertension (blood pressure Ͼ140/90 mmHg), and renal impairment (serum creatinine Ͼ120 mol/ l). None of the subjects was on any medications for Ն6 months before the study, including glucocorticoids, antidiabetes drugs, antiobesity drugs, and lipidlowering agents or antihypertensive medication. The local research ethics committee approved the study, and all patients involved gave their informed consent, in accordance with the guidelines in the Declaration of Helsinki, 2000. adipose tissue explants was measured by ELISA (R&D Systems, Abingdon, U.K.), according to the manufacturer's protocol, with an intra-assay coefficient of variation of Ͻ5%.
Primary explant culture
Adipose tissue explants were cultured with or without the addition of insulin (Sigma-Aldrich), mitogen-activated protein kinase kinase (MEK) inhibitor (U0126; Calbiochem, San Diego, CA), or phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002; Calbiochem) as previously described (6) .
Western blotting
Protein lysates were prepared and Western blotting was performed as previously described (6) . We used monoclonal primary mouse anti-human antibody for lipocalin-2 (Abcam, Cambridge, U.K.) (1: 500 dilution) and monoclonal primary rabbit anti-human antibody for ␤-actin (Cell Signaling Technology, Beverly, MA) (1:1,000 dilution).
Statistics
Data were analyzed by Student's t test, Mann-Whitney U test, and/or Friedman's ANOVA according to the number of groups compared. P Ͻ 0.05 was considered significant.
RESULTS -Insulin infusion resulted in elevation of fasting insulinemia from 78.1 Ϯ 12.0 pmol/l to 294.6 Ϯ 31.0 pmol/l. Insulin levels remained elevated until the end of the prolonged insulinglucose infusion (366.0 Ϯ 37.0 pmol/l). Lipocalin-2 levels remained unaltered throughout the control day from 91.2 Ϯ 21.5 ng/ml between 0800 and 1000 h to 82.8 Ϯ 21.9 ng/ml between 0800 and 1000 h the next day ( Fig. 1A ; P Ͼ 0.05).
There was a profound effect of insulin on lipocalin-2 levels over 26 h of insulin infusion: from 103.2 Ϯ 17.9 ng/ml between 0800 and 1000 h to 159.7 Ϯ 34.5 ng/ml between 0800 and 1000 h the following day ( Fig. 1A ; P Ͻ 0.01). The increase in lipocalin-2 levels was relatively acute approaching maximal values at 4 h (180.8 Ϯ 45.7 ng/ml) ( Fig. 1A ; P Ͻ 0.01) and persisting throughout the entire period of hyperinsulinemia.
Lipocalin-2 protein production and secretion into conditioned media were significantly increased dose dependently by insulin from human omental adipose tissue explants; these effects were negated by both PI3K inhibitor (LY294002; 50 mol/l) and MEK inhibitor (U0126; 10 mol/l) ( Fig. 1B-E ; *P Ͻ 0.05, **P Ͻ 0.01, ##P Ͻ 0.01). Treatment of adipose tissue explants with either LY294002 or U0126 alone did not affect lipocalin-2 levels (data not shown).
CONCLUSIONS -Our findings highlight the involvement of both PI3K and mitogen-activated protein kinase signaling pathways in insulin-induced lipocalin-2 production and may explain the increased lipocalin-2 levels in hyperinsulinemic subjects (4). Our observations may have clinical/therapeutic applications, given that lipocalin-2 promotes insulin resistance in adipocytes and hepatocytes (3) .
It should be emphasized that our study utilized relatively small numbers of subjects because of the challenge imposed by the prolonged insulin-glucose infusion study. Additionally, we studied a relatively short-term effect of hyperinsulinemia (24 h) in healthy subjects because type 2 diabetes and insulin resistance syndromes are more chronic states of hyperinsulinemia. Nevertheless, our observations are highly consistent and significant and raise interesting questions on the mechanisms regulating lipocalin-2 production.
In conclusion, we show for the first time the potent and robust regulation of lipocalin-2 by insulin ex vivo and in vivo. Our findings provide novel insights into lipocalin-2 physiology, which may be pertinent to hyperinsulinemic states such as obesity and diabetes.
